PLX
Protalix BioTherapeutics, Inc. (AMEX)
Healthcare — Biotechnology
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Price History
Fundamentals
| Market Cap | $185.31M |
| P/E Ratio (TTM) | 12.11 |
| Forward P/E | 3.71 |
| EPS (TTM) | $0.19 |
| Dividend Yield | - |
| Profit Margin | 20.07% |
| Revenue Growth | 233.70% |
| ROE | 27.27% |
| Debt/Equity | 12.62 |
| Recommendation | None |
| Analyst Target | $11.00 |
| Analysts | 2 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 72.6 |
| Beta | 0.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.19 |
| 52-Week Low | $1.36 |
| 50-Day Avg | $2.08 |
| 200-Day Avg | $2.20 |
| Avg Volume | 735.8K |
| Volume | 436.2K |
Performance Analysis
BULLISHPLX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report